94749-08-3 Usage
Description
Different sources of media describe the Description of 94749-08-3 differently. You can refer to the following data:
1. Salmeterol hydroxynaphthoate is a new long-acting β2-selective adrenoceptor agonist
introduced as a bronchodilator for the treatment of reversible airway obstruction in asthma
and chronic bronchitis. It has bronchodilatory activity as intense and four times longerlasting
than equivalent doses of salbutamol. Salmeterol hydroxynaphthoate is reported to
be the first bronchodilator with significant anti-inflammatory activity and hence could
complement prophylactic corticosteroid therapy.
2. Salmeterol is a long-acting β2-adrenergic receptor agonist (β2-AR; EC50s = 0.79, 63.1, and 9.4 nM for β2-, β1-, and β3-ARs, respectively). It inhibits electrically-stimulated contraction of isolated guinea pig trachea strips (EC50 = 2.51 nM) and histamine-induced bronchoconstriction in guinea pigs via aerosol administration of doses ranging from 0.12 to 12 mM. Salmeterol binds to an exosite domain of β2-adrenergic receptors, producing a slow onset of action and prolonged activation. Formulations containing salmeterol have been used in the treatment of asthma, including exercise-induced asthma, and chronic obstructive pulmonary disease.
Chemical Properties
White to Off-White Solid
Uses
Different sources of media describe the Uses of 94749-08-3 differently. You can refer to the following data:
1. A ?-Adrenergic agonist. Structural analog of albuterol
2. A β2-Adrenergic agonist. Structural analog of Albuterol (A514500).
3. Smooth wheezing anti-inflammatory
4. Bronchodilator; Beta2-adrenoceptor agonist
Brand name
Serevent (GlaxoSmithKline).
Biochem/physiol Actions
β2-adrenoceptor agonist.
Check Digit Verification of cas no
The CAS Registry Mumber 94749-08-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,4,7,4 and 9 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 94749-08:
(7*9)+(6*4)+(5*7)+(4*4)+(3*9)+(2*0)+(1*8)=173
173 % 10 = 3
So 94749-08-3 is a valid CAS Registry Number.
InChI:InChI=1/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2/t25-/m0/s1
94749-08-3Relevant articles and documents
Preparation method of Salmeterol Xinafoate
-
, (2017/08/27)
The invention discloses a preparation method of Salmeterol Xinafoate. The method comprises the following steps: condensation reaction of a compound 2 and a compound 3 under alkaline conditions to obtain an intermediate 4; acidic hydrolysis to obtain an intermediate 5, and reduction reaction of the intermediate 5 to obtain an intermediate 6; debenzylation of the intermediate 6 by use of palladium carbon (Pd / C) to obtain a salmeterol basic group; and salification from the salmeterol basic group and 1-hydroxy-2-naphthoic acid to obtain the Salmeterol Xinafoate. The preparation method has the advantages of mild reaction condition, simple post-treatment, low cost, high yield, high product purity and easy industrialization.
PROCESS FOR THE PREPARATION OF SALMETEROL AND ITS INTERMEDIATES
-
, (2012/03/27)
The present invention discloses a process for the preparation of methyl 2-(benzyloxy)- 5-(2-bromoacetyl)benzoate (V), comprising: (d) benzylating methyl-5-acetyl-2-hydroxybenzoate (VIII) with benzyl chloride in the presence of a base and a catalyst in a suitable polar solvent to obtain 5-acetyl-2- benzyloxy benzoate (VII); (e) brominating methyl 5-acetyl-2-(benzyloxy)benzoate (VII) with a suitable brominating agent in one or more suitable' solvents in the presence of an acid catalyst to obtain methyl 2-(benzyloxy)-5-(2-bromoacetyl)benzoate V; (c) optionally, purifying the methyl 2-(benzyloxy)-5-(2-bromoacetyl)benzoate (V) in a suitable solvent; and (f) isolating the methyl 2-(benzyloxy)-5-(2-bromoacetyl)benzoate (V).
Novel process for preparing salmeterol
-
, (2008/06/13)
Accordingly, the present invention provides a process for the preparation of a compound of formula (I) or a single enantiomer thereof, or a salt or a solvate thereof, wherein W is a chiral auxiliary or hydrogen and P1 and P2 are each